These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 9560052

  • 1. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
    Bokemeyer C.
    Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
    [Abstract] [Full Text] [Related]

  • 2. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ.
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [Abstract] [Full Text] [Related]

  • 3. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
    Hartmann JT, Kuczyk MA, Kollmannsberger C, Kanz L, Bokemeyer C.
    World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ.
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and treatment of patients with testicular germ cell cancer.
    Hartmann JT, Kanz L, Bokemeyer C.
    Drugs; 1999 Aug; 58(2):257-81. PubMed ID: 10473019
    [Abstract] [Full Text] [Related]

  • 6. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
    Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L.
    World J Urol; 1996 Aug; 14(6):354-9. PubMed ID: 8986035
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 9. High-dose chemotherapy in germ-cell tumors.
    Droz JP, Culine S, Biron P, Kramar A.
    Ann Oncol; 1996 Dec 15; 7(10):997-1003. PubMed ID: 9037356
    [Abstract] [Full Text] [Related]

  • 10. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
    Fléchon A, Biron P, Philip I, Blay JY, Droz JP.
    Bull Cancer; 1999 Apr 15; 86(4):391-9. PubMed ID: 10341344
    [Abstract] [Full Text] [Related]

  • 11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D.
    J Clin Oncol; 1994 Jun 15; 12(6):1223-31. PubMed ID: 7911158
    [Abstract] [Full Text] [Related]

  • 12. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M.
    J Clin Oncol; 1996 Oct 15; 14(10):2631-7. PubMed ID: 8874321
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP.
    J Urol; 1997 Mar 15; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P, Garrino C, Bensmaïne MA, Bekradda M, Brain E, Di Palma M, Goupil A, Misset JL, Cvitkovic E.
    J Cancer Res Clin Oncol; 1999 Dec 15; 125(12):707-11. PubMed ID: 10592105
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O, Siegert W, Beyer J.
    Cancer Treat Rev; 2001 Oct 15; 27(5):283-8. PubMed ID: 11871864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.